Literature DB >> 6319504

Production of intraepidermal microabscesses by topical application of leukotriene B4.

R Camp, R R Jones, S Brain, P Woollard, M Greaves.   

Abstract

Leukotriene B4 is a highly potent leukocyte chemotactic compound. It has been identified in chamber fluid and scale from psoriatic skin lesions, in which epidermal neutrophil infiltration is reported to be one of the earliest pathologic events. The ability of leukotriene B4 to reproduce the inflammatory events of psoriasis, by topical application to the skin of normal human volunteers, was thus studied. Persistent visible inflammatory reactions were elicited by application of amounts of leukotriene B4 as low as 5 ng, and the maximum diameters of the reactions were dose-related up to at least 500 ng. The visible reactions appeared 12-24 h after initial application of leukotriene B4, and persisted for several days, leaving brownish pigmentation and scaling at 7 days. Histologic examination showed intraepidermal neutrophil microabscesses at 24 h, but these had resolved by 48 h. A mixed, perivascular neutrophil and mononuclear cell infiltrate was seen in the dermis at 24 h, becoming predominantly mononuclear after 24 h. Nonspecific chemical irritant contact dermatitis was excluded by the absence of reactions to high doses of two chemically similar metabolites of arachidonic acid which lack significant in vitro chemokinetic activity. These experiments provide further evidence for the role of leukotriene B4 in the pathogenesis of psoriasis, and may lead to the development of an experimental model of the inflammatory events in psoriasis, and of a simple in vivo test of neutrophil function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319504     DOI: 10.1111/1523-1747.ep12259945

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  32 in total

1.  Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) and 5,12-dihydroxyeicosatetraenoic acid (leukotriene B4) in psoriasis and normal human skin.

Authors:  P M Dowd; A K Black; P W Woollard; M W Greaves
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

2.  Heterogeneous distribution of lipoxygenase products in psoriatic skin lesions.

Authors:  K Fogh; J Kiil; T Herlin; T Ternowitz; K Kragballe
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation.

Authors:  D Aked; S J Foster; A Howarth; M E McCormick; H C Potts
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

4.  LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Evidence for different LTA4 hydrolase activity in human lymphocytes and human skin.

Authors:  L Iversen; B Deleuran; A M Hoberg; K Kragballe
Journal:  Arch Dermatol Res       Date:  1996-05       Impact factor: 3.017

5.  Transendothelial cell diapedesis of neutrophils in inflamed human skin.

Authors:  C Schubert; E Christophers; O Swensson; T Isei
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 6.  Perspectives in corticosteroid research.

Authors:  M Töpert
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Chemotactic lipoxygenase products in sera from patients with psoriasis.

Authors:  K Fogh; T Ternowitz; K Kragballe; T Herlin
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

Review 8.  Leukotrienes in inflammation.

Authors:  M A Bray
Journal:  Agents Actions       Date:  1986-10

9.  Guinea pig epidermis generates putative anti-inflammatory metabolites from fish oil polyunsaturated fatty acids.

Authors:  C Miller; R Y Yamaguchi; V A Ziboh
Journal:  Lipids       Date:  1989-12       Impact factor: 1.880

10.  Interleukin-8 stimulates the formation of 15-hydroxy-eicosatetraenoic acid by human neutrophils in vitro.

Authors:  K Fogh; C G Larsen; L Iversen; K Kragballe
Journal:  Agents Actions       Date:  1992-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.